comparemela.com

Latest Breaking News On - Institutional investors weigh in on galmed pharmaceuticals - Page 2 : comparemela.com

Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by Analysts at StockNews com

StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a report published on Sunday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Separately, Maxim Group upgraded Galmed Pharmaceuticals from a hold rating to a buy rating in a research report on Monday, July 24th. View Our Latest Stock […]

Galmed Pharmaceuticals (NASDAQ:GLMD) Receives New Coverage from Analysts at StockNews com

StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a research report sent to investors on Saturday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Separately, Maxim Group raised shares of Galmed Pharmaceuticals from a hold rating to a buy rating in a report on Monday, July 24th. […]

Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews com

StockNews.com started coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a report released on Monday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Galmed Pharmaceuticals Stock Performance Shares of NASDAQ GLMD opened at $2.56 on Monday. Galmed Pharmaceuticals has a fifty-two week low of $2.52 and a fifty-two […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.